Androgen Receptor is a Determinant of Melanoma Targeted Drug Resistance
A. Samarkina, M. K. Youssef, P. Ostano, S. Ghosh, M. Ma, B. Tassone, T. Proust, G. Chiorino, M. P. Levesque, G.-P. Dotto
This study shows that androgen receptor activity contributes to melanoma resistance to BRAF/MEK inhibitors and suggests targeting AR could improve treatment outcomes.
bioRxiv · May 27, 2022Cancer Biology